Share
Market Research Report

AXIAL SPONDYLOARTHRITIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By TypeAnkylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
  • By TherapeuticsNonsteroidal Anti-Inflammatory Drugs (NSAIDs) (Meloxicam, Naproxen, Celecoxib, Diclofenac, Others (Indomethacin, etc.)) · Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) (TNF inhibitors, Conventional DMARDs, and Others (Corticosteroids, etc.)) · By Route of Administration (Oral, Subcutaneous (SC) Injections, and Intravenous (IV) Infusions) · By Product Type (Branded and Generic) · By Gender (Female and Male) · By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) · By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Rehabilitation & physiotherapy centers, and Others (Academic and Research Institutes, etc.)) · By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa
  • Published In11 Mar 2026
  • Report CodeCMI8165
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  •  Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Ankylosing Spondylitis
    • Non-radiographic Axial Spondyloarthritis

  •  Therapeutics Insights (Revenue, USD Bn, 2021 - 2033)

    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
      • Meloxicam
      • Naproxen
      • Celecoxib
      • Diclofenac
      • Others (Indomethacin, etc.)
    • Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
      • TNF inhibitors
      • Adalimumab
      • Infliximab
      • Etanercept
      • Others (Golimumab, etc.)
    • IL-17 inhibitors
      • Secukinumab
      • Ixekizumab
      • Others (Bimekizumab, etc.)
    • JAK inhibitors
      • Tofacitinib
      • Upadacitinib
    • Conventional DMARDs
      • Sulfasalazine
      • Methotrexate
    • Others (Corticosteroids, etc.)

  •  Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)

    • Oral
    • Subcutaneous (SC) Injections
    • Intravenous (IV) Infusions

  •  Product Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Branded
    • Generic

  •  Gender Insights (Revenue, USD Bn, 2021 - 2033)

    • Female
    • Male

  •  Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

  •  End User Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Rehabilitation & physiotherapy centers
    • Others (Academic and Research Institutes, etc.)

  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa